Augmenting Demand for Fluoxetine in China Led by Rising Cases of Depression : Ken Research - PowerPoint PPT Presentation

Loading...

PPT – Augmenting Demand for Fluoxetine in China Led by Rising Cases of Depression : Ken Research PowerPoint presentation | free to download - id: 8181a7-YzFiO



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Augmenting Demand for Fluoxetine in China Led by Rising Cases of Depression : Ken Research

Description:

Antidepressant Demand China - Get latest market reports like Chinese Lifestyle and Adult Depression, China Fluoxetine Future Outlook, Number of Population under Stress in China, UK China Fluoxetine Market size online at kenresearch.com – PowerPoint PPT presentation

Number of Views:5

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Augmenting Demand for Fluoxetine in China Led by Rising Cases of Depression : Ken Research


1
Augmenting Demand for Fluoxetine in China Led by
Rising Cases of Depression
2
  • Rising cases of suicide death toll of depression
    around the world is up to 1.0 million people and
    the number of depression patients in China has
    reached 90 million.
  • There is a broad demand of antidepressant
    medicines in China where Fluoxetine is growing at
    a CAGR of 9.68 during 2010-2014.
  • Ken Research introduces its latest publication
    on, Investigation Report on China Fluoxetine
    Market, 2010-2019, which offers detailed
    insights into the changing trends within the
    Chinese pharmaceuticals industry. The focus is
    primarily on the increasing demand for
    antidepressants such as Fluoxetine led by rising
    cases of depression. A detailed profile of
    Fluoxetine including its sales position, market
    share and pricing in the Chinese market has also
    been discussed in the investigative report.

3
  • The World Health Organization has forecasted that
    the number of depression patients will be second
    largest worldwide by 2020. Additional figures
    report that almost 1 million people commit
    suicide under the influence of depression
    globally, every year. Research has revealed even
    alarming figures for China showcasing almost 90
    million people in China are currently being
    suffering from symptoms of depression, out of
    which only 30 are seeking medical advice.
    Furthermore, clinical experience shows that 80
    of the patients can achieve clinical cure, if
    having standard treatment, expect very few
    patients with refractory type, others will be
    improvement.

4
  • With such a widening gap between people suffering
    from depressions and the use of medicines to
    treat the same, producers of antidepressants are
    facing increasing demand within the Chinese
    pharmaceutical industry. Fluoxetine is the most
    preferred drug for treating depression worldwide.
    Original antidepressants Fluoxetine produced by
    Eli Lilly and Company was approved for the
    treatment of depression first in Belgium in 1986.

5
  • There is a broad demand of Fluoxetine in China.
    This demand is primarily driven by the increasing
    aspirations of people about the quality of life
    they lead. In order to enhance their lifestyle,
    people in China are working harder which causes
    depression. Eli Lilly and Company named their
    products "the optimal solution" (Prozac) which is
    used for the treatment of adult depression,
    obsessive-compulsive disorder and neurological
    bulimia in clinical practice as well as panic
    disorder with or without agoraphobe.

6
  • Global Antidepressants Industry
  • The global pharmaceutical industry has reported
    fast growth in the past few years, with
    antidepressants being amongst the leading drugs
    in terms of value and volume of output.
    Reportedly, more than a 100 million people are
    affected by depression globally, resulting in the
    exponential expansion of antidepressants market.
    At present, Canadians are frontrunners in terms
    of total national usage of anti-depressants with
    the US not far behind. However, China is expected
    to report the fastest growth in terms of volume
    and value of output. The leading players within
    the global antidepressants industry include
    Wyeth, GlaxoSmithKline, Pfizer, Forest
    Laboratories, AstraZeneca, Eli Lilly,
    Bristol-Myers Squibb Company, Schering-Plough and
    H. Lundbeck.

7
  • Some of the drivers in the global antidepressants
    industry include
  • Increasing number of people under stress and
    depression
  • Increases awareness about the importance of
    considering depression a serious medical
    condition
  • Increased marketing and advertising efforts by
    manufacturers of antidepressants
  • Key Topics Covered in the Report
  • Detailed explanation of concepts of Fluoxetine
  • Sales situation of Fluoxetine in global market
  • Market profile of Fluoxetine in China
  • Sales situation of Fluoxetine in China
  • Market share of major fluoxetine producers in
    China
  • Profilers of leading players in Chinese
    Fluoxetine market
  • Future outlook for Fluoxetine in China, 2015-2019
  • Forecast of market scale
  • Forecast of competition pattern

8
  • To know more on coverage, click on the link
    below
  • https//www.kenresearch.com/healthcare/pharmaceuti
    cals/investigation-report-china-fluoxetine-market/
    8491-91.html
  • Related Reports
  • https//www.kenresearch.com/healthcare/pharmaceuti
    cals/respiratory-depression-pipeline/9515-91.html
  • https//www.kenresearch.com/healthcare/pharmaceuti
    cals/treatment-resistant-depression-pipeline/9646-
    91.html
  • ContactKen Research Ankur Gupta, Head
    Marketing Communicationsquery_at_kenresearch.com
    91-124-4230204

9
Thank you
About PowerShow.com